These cross appeals are filed by the Revenue and Assessee against order dated 12.03.2020 passed by the CIT(A)-1, Ahmedabad for the Assessment Year 2012-13.

2. The Revenue has raised the following grounds of appeal :-

ITA Nos.345 & 383/Ahd/2020 Assessment Years: 2012-13 "(1) The ld. CIT(A) has erred in facts and law in deleting the transfer pricing adjustment made in respect of Corporate guarantee fees of Rs.60,83,440/-

(2) The id. CIT(A) has erred in facts and law in deleting the interest disallowance of Rs.1,64,86,560/- u/s.36(1)(iii) of the Act.

These cross appeals are filed by the Revenue and Assessee against order dated 12.03.2020 passed by the CIT(A)-1, Ahmedabad for the Assessment Year 2012-13.

2. The Revenue has raised the following grounds of appeal :-

ITA Nos.345 & 383/Ahd/2020 Assessment Years: 2012-13 "(1) The ld. CIT(A) has erred in facts and law in deleting the transfer pricing adjustment made in respect of Corporate guarantee fees of Rs.60,83,440/-

(2) The id. CIT(A) has erred in facts and law in deleting the interest disallowance of Rs.1,64,86,560/- u/s.36(1)(iii) of the Act.

The Drug-Releasing Contact Lens Contains a Broad-Spectrum Antibiotic

The Glint Drug-Releasing Contact Lens is a Platform Technology for Ocular Therapy

Veronique Michaud, PhD, is honored for her contributions as the president and co-founder of GalenusRx

Stephen Pham, PhD, recognized as Senior Vice President, Product Development at Avalyn Pharma Inc.

Paul Krauthauser is a pharmaceutical expert who excels in building high-functioning, high-performance teams

Heather D. Embree, MS, honored for her leadership and expertise in program management and drug development

Yue "Melody" Yin is an expert in clinical trial research in the pharmaceuticals and biotechnology industry

David is distinguished as a retired executive in pharmaceuticals and public health for more than 30 years

Jan M. Lundberg is a retired pharmaceutical researcher with over 30 years of professional success

Charu Yerneni, PhD, is a distinguished expert in pharmaceutical analysis with more than a decade of experience

Stephanie M. Chosa has been recognized for her success in leadership as a director of pharmacy

Targeted therapy for lung cancer is based on personalized medicine approach

Personalized and targeted medicine for rare lung and other cancers

Conference Highlights Key Features of Successful Clinical Trial Management

Dennis Harris is a distinguished professional with decades of leadership experience in pharmaceuticals

Chardae Rodgers-Gamble, DBA, is a seasoned expert and founder of CR Clinical and Jackson Taylor Therapeutics

Yacine M. Amrani, PharmD, PhD, MBA, is honored for his experience as a research scientist and healthcare strategist, leading to his current work as a senior director of business development at PTC Therapeutics Inc.

Investigation to initiate in Q2 2023

The Glint Drug-Releasing Contact Lens Replaces Standard Eye Drops

The first Glint product, MoxiLens™, is an antibiotic releasing contact lens.

Zhonggai "Kevin" Li, PhD, is lauded as a senior director of biostatistics at Sumitomo Pharma Oncology

Mario DiPaola is noted for his pioneering cancer treatments at Therabene Inc

Katherine Hester, MD, PhD, RAC, is noted for her success in clinical research and regulatory submissions

The Syntegon Versynta FFP is an individually configurable machine with an integratable isolator for filling aseptic and highly potent liquid active ingredients.

Cost reduction is a focus for many at the moment and understandably so. Multinational pharmaceutical company, Glenmark, is just one of those businesses looking at how it can optimise its costs globally.

Aramex UK has urged pharmaceutical companies exporting products overseas to be mindful about shipping to warmer climates.

Single-domain antibodies (sdAbs) demonstrate favorable pharmacokinetic profiles for molecular imaging applications. However, their renal excretion and retention are obstacles for applications in targeted radionuclide therapy (TRT). Methods: Using a click-chemistry–based pretargeting approach, we aimed to reduce kidney retention of a fibroblast activation protein α (FAP)–targeted sdAb, 4AH29, for ¹⁷⁷Lu-TRT. Key pretargeting parameters (sdAb-injected mass and lag time) were optimized in healthy mice and U87MG (FAP⁺) xenografts. A TRT study in a pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (PDX) model was performed as a pilot study for sdAb-based pretargeting applications. Results: Modification of 4AH29 with trans-cyclooctene (TCO) moieties did not modify the sdAb pharmacokinetic profile. A 200-µg injected mass of 4AH29-TCO and an 8-h lag time for the injection of [¹⁷⁷Lu]Lu-DOTA-PEG₇-tetrazine resulted in the highest kidney therapeutic index (2.0 ± 0.4), which was 5-fold higher than that of [¹⁷⁷Lu]Lu-DOTA-4AH29 (0.4 ± 0.1). FAP expression in the tumor microenvironment was validated in a PDAC PDX model with both immunohistochemistry and PET/CT imaging. Mice treated with the pretargeting high-activity approach (4AH29-TCO + [¹⁷⁷Lu]Lu-DOTA-PEG₇-tetrazine; 3 x 88 MBq, 1 injection per week for 3 wk) demonstrated prolonged survival compared with the vehicle control and conventionally treated ([¹⁷⁷Lu]Lu-DOTA-4AH29; 3 x 37 MBq, 1 injection per week for 3 wk) mice. Mesangial expansion was reported in 7 of 10 mice in the conventional cohort, suggesting treatment-related kidney morphologic changes, but was not observed in the pretargeting cohort. Conclusion: This study validates pretargeting to mitigate sdAbs’ kidney retention with no observation of morphologic changes on therapy regimen at early time points. Clinical translation of click-chemistry–based pre-TRT is warranted on the basis of its ability to alleviate toxicities related to biovectors’ intrinsic pharmacokinetic profiles. The absence of representative animal models with extensive stroma and high FAP expression on cancer-associated fibroblasts led to a low mean tumor-absorbed dose even with high injected activity and consequently to modest survival benefit in this PDAC PDX.

Attorney General Kathy Jennings announced today a $150 million multistate settlement in principle with opioid manufacturer Hikma Pharmaceuticals (Hikma) for its role in fueling the opioid crisis. Hikma produces a range of generic opioid products and sells hundreds of millions of opioid doses every year. The attorneys general allege that from 2006 to 2021, Hikma […]

Delaware Attorney General Kathy Jennings today announced a multistate settlement in principle with opioid manufacturer Amneal Pharmaceuticals (Amneal) for its role in fueling the nationwide epidemic of opioid addictions and overdoses. Amneal produces several generic opioid products and was one of the largest manufacturers of opioids from 2006 to 2019, selling nearly nine billion pills. […]

The Park Family�s Infertility Story

Ask About the Curve Public Service Announcement

Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients

Anti-Fibrotic Data from Amira Pharmaceuticals' LPA1 Receptor Antagonist Program Published in the British Journal of Phar

Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO

ADVENTRX Pharmaceuticals Announces Closing of Financing

Cadence Pharmaceuticals Reports First Quarter 2010 Financial Results

Trubion Pharmaceuticals, Inc. Reports First-Quarter 2010 Financial Results

Keryx Biopharmaceuticals Initiates Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Patient

DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent

Arena Pharmaceuticals Announces First Quarter 2010 Financial Results and Recent Developments

The drug, marketed as Hamsyl – Junior will now be available in a 1500 IU pack, and is priced at ₹Rs 20,970, a company official told businessline

J.B. Chemicals and Pharmaceuticals share price can rise to ₹2,100

National Bureau of Economic Research

Recent seizures of fake medical supplies being marketed as protection against Covid-19 underscore the need to address a growing international trade in counterfeit pharmaceuticals that is costing billions of euros a year and putting lives at risk, according to the OECD and the EU’s Intellectual Property Office.

Recent seizures of fake medical supplies being marketed as protection against coronavirus (Covid-19) have underscored the need to address a growing international trade in counterfeit pharmaceuticals. The trafficking of fake or defective medicines is costly and puts lives at risk, according to the new OECD and EU reports.